Analyst Yun Zhong of Wedbush maintained a Buy rating on MannKind (MNKD – Research Report), retaining the price target of $11.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Yun Zhong’s rating is based on MannKind’s strategic position in the market and its potential for growth. The company is set to benefit from its partnership with United Therapeutics, particularly through the royalties from Tyvaso DPI, which is expected to see significant revenue growth. This partnership provides MannKind with a stable revenue stream and potential upside as Tyvaso DPI expands into new indications.
Moreover, the competitive landscape and MannKind’s innovative approach in the inhaled therapeutics space further support the Buy rating. The company’s focus on developing unique delivery systems for complex medications positions it well to capture market share and drive future growth. These factors combined with a favorable market outlook contribute to Yun Zhong’s positive assessment of MannKind’s stock.